Earnings Call Transcripts

Access detailed transcripts and key takeaways from company earnings calls

All Earnings Calls

LH February 17, 2026

Labcorp Q4 2025 Earnings Call - Specialty Testing and Central Lab Backlog Power Mid‑Single Digit Revenue Outlook

Labcorp closed 2025 with clear momentum: revenue up low‑single digits in Q4 and over 7% for the year, adjusted EPS up double digits, margin expansion, and a healthy central lab backlog that underpins ...

  • 2025 momentum, with enterprise revenue up over 7% for the year, adjusted EPS up ~13% for the year, and enterprise margins expanding over 50 basis points year-over-year.
  • Q4 2025 results: revenue $3.5 billion, up 5.6% YoY; adjusted operating income $488 million (13.9% margin); adjusted EPS $4.07, up 18% YoY.
  • Free cash flow for full-year 2025 was $1.2 billion, up 10%; Q4 free cash flow was $490 million, down YoY due to working capital timing and $258 million of acquisition spend in the quarter.
  • +12 more takeaways
ET February 17, 2026

Energy Transfer Fourth Quarter 2025 Earnings Call - Pipeline buildout and project ramp drive upgraded EBITDA guidance and heavy capex discipline

Energy Transfer reported a record near $16 billion of adjusted EBITDA for 2025, with fourth quarter EBITDA of about $4.2 billion and DCF roughly flat at $2.0 billion in Q4 versus year-ago. Management ...

  • Record adjusted EBITDA for full-year 2025 at nearly $16.0 billion, up about 3% year over year; Q4 adjusted EBITDA approximately $4.2 billion.
  • Distributable cash flow, attributable to partners, was $8.2 billion for 2025, down slightly from $8.4 billion in 2024; Q4 DCF was about $2.0 billion, roughly flat with Q4 2024.
  • 2026 organic growth capital guidance set at $5.0-5.5 billion, excluding Sun and USA Compression, with roughly two-thirds allocated to natural gas projects and ~25% to NGL and refined products expansions.
  • +11 more takeaways
FELE February 17, 2026

Franklin Electric Q4 2025 Earnings Call - Margin Gains, New Products and a Value Acceleration Push Set Stage for 2026

Franklin Electric closed 2025 with topline and operating income gains, driven by price realization, selective M&A and productivity actions. Full-year sales rose 5.4% to $2.1 billion and segment operat...

  • Full-year 2025 sales were $2.1 billion, up 5.4% year-over-year; Q4 sales rose 4.4% to $506.9 million.
  • Segment operating income was up 9.6% for the year, and consolidated operating income rose 10% to $269.0 million in 2025.
  • GAAP diluted EPS was $3.22 in 2025 versus $3.86 in 2024, reduced by a $41.5 million pension settlement charge (net of tax) equal to $0.91 per share; adjusted EPS was $4.14 versus $3.92 in 2024, up 6%.
  • +12 more takeaways
CNH February 17, 2026

CNH Q4 2025 Earnings Call - Tariff Drag and Dealer Destocking Meet Cost Cuts and Product Push

CNH closed Q4 with a mixed bag: quarter-over-quarter operational improvements and a stronger Q4 revenue compare, but the company is navigating a heavier tariff burden and uneven regional demand. Q4 in...

  • Q4 consolidated revenues were $5.2 billion, up 6% year-over-year, helped by an easy Q4 2024 comp when production was severely cut.
  • Industrial net sales in Q4 rose 8% to nearly $4.5 billion; industrial adjusted EBIT was $234 million, up 21% year-over-year.
  • Adjusted net income for Q4 was $246 million, with adjusted diluted EPS of $0.19 versus $0.15 in Q4 2024.
  • +16 more takeaways
VMI February 17, 2026

Valmont Industries Q4 2025 Earnings Call - Utility backlog and capacity investments set up 2026 growth

Valmont closed 2025 with a pivot toward utility-led growth. Backlog climbed to $1.5 billion, up 22% year-over-year, and management has been plowing cash and capital into capacity, automation, and AI-e...

  • Backlog increased to about $1.5 billion, up 22% year-over-year, driven largely by utility projects and multi-year customer plans into 2027 and beyond.
  • GAAP EPS for Q4 was $9.05, materially boosted by a $78.5 million U.S. tax benefit tied to the Prospera loss, equivalent to $3.98 per share; adjusted EPS excludes that item.
  • Adjusted Q4 diluted EPS was $4.92, up 28.1% year-over-year; adjusted full-year diluted EPS was $19.09, up 11.1% versus 2024.
  • +11 more takeaways
ETOR February 17, 2026

eToro Q4 2025 Earnings Call - AI-First Super App Push, 24/7 Trading and Diversified Revenue Hold Up While Crypto Slumps

eToro closed 2025 with resilient profitability and clear strategic thrusts: management is pushing an AI-first super app, accelerated 24/7 market access, and deeper on-chain product integration while l...

  • Full-year 2025 net contribution rose 10% to $868 million, Q4 net contribution was $227 million, a 6% sequential increase.
  • Adjusted EBITDA for the year was $317 million, Q4 adjusted EBITDA was $87 million, delivering a 38% adjusted EBITDA margin in the quarter.
  • eToro cites resilience from its multi-asset model, with capital markets net trading contribution up 43% YoY to $116 million, while crypto net trading contribution fell 72% YoY to $26 million.
  • +12 more takeaways
GPC February 17, 2026

Genuine Parts Company Q4 2025 Earnings Call - Plans to Split into Separate Automotive and Industrial Public Companies

Genuine Parts Company opened a hard new chapter, announcing an intended split into two standalone public companies: Global Automotive, led by the NAPA franchise, and Global Industrial, anchored by Mot...

  • GPC announced intent to separate into two independent public companies: Global Automotive (NAPA-led) and Global Industrial (Motion). Targeted separation completion in Q1 2027, investor days planned in H2 2026, separation to be tax-free to shareholders.
  • Management says the split will create clearer strategic focus and capital allocation, with each company targeting an investment-grade credit rating and tailored M&A and return programs.
  • 2025 consolidated sales were $24.3 billion, up 3.5% year over year, with gross margin expansion for the third consecutive year and approximately $470 million invested in supply chain and technology.
  • +13 more takeaways
DFIN February 17, 2026

Donnelley Financial Solutions Fourth Quarter 2025 Earnings Call - Transformation Drives Record Margins as Software Mix Offsets Transaction Decline

DFIN closed 2025 with a clean, unmistakable pivot: higher-margin software and a tighter cost structure delivered record Adjusted EBITDA margins even as legacy transactional revenue continued to slide....

  • Q4 2025 total net sales were $172.5 million, up 10.4% year over year, exceeding the high end of guidance primarily due to stronger-than-expected transactional volume.
  • Full-year 2025 consolidated Adjusted EBITDA was $239.8 million, up $22.5 million or 10.4% year over year, with a record full-year Adjusted EBITDA margin of 31.3%, roughly 350 basis points higher than 2024.
  • Q4 Adjusted EBITDA was $45.8 million with a Q4 Adjusted EBITDA margin of 26.6%, an improvement of about 630 basis points versus Q4 2024.
  • +15 more takeaways
NEO February 17, 2026

NeoGenomics Q4 & FY 2025 Earnings Call - Clinical Momentum and RaDaR ST Launch Signal NGS-Driven Growth

NeoGenomics closed 2025 with record revenue and clear strategic momentum, driven by double-digit clinical growth and rapid NGS adoption. Management is pivoting deliberately from low-value, high-volume...

  • Q4 2025 revenue was $190.0 million, up 11% year‑over‑year; full year 2025 revenue was $727.0 million, up 10% versus 2024.
  • Clinical revenue grew 16% year‑over‑year in Q4, and full‑year clinical revenue increased 15% (13% ex PathLine).
  • NGS revenue jumped 23% in the quarter, and NGS now represents roughly one third of clinical revenue while accounting for only ~9%–10% of test volume.
  • +15 more takeaways
MDT February 17, 2026

Medtronic Q3 FY2026 Earnings Call - PFA-fueled CAS Surge and Early-Stage Launches Point to Durable Growth Acceleration

Medtronic delivered a beat and a clear message, growth is broadening beyond the pulsed field ablation surge. Q3 revenue was $9.0 billion, up 8.7% reported and 6% organic, led by cardiovascular at +11%...

  • Revenue $9.0 billion, grew 8.7% reported and 6% organic, 50 bps acceleration vs prior quarter and 50 bps above guidance.
  • Cardiovascular portfolio up 11% year over year, 13% growth in the U.S., the strongest cardiovascular performance in a decade excluding COVID comps.
  • CAS (pulsed field ablation) grew 80% year over year, with PFA accounting for 80% of CAS revenue, and management expects continued high-teens to double-digit market growth into FY2027.
  • +12 more takeaways